Skip to contentClarengateINTELLIGENCE
Coverage & freshness About Clarengate
Companies/SC467513

Elasmogen Limited

Private Limited Company · Foresterhill

ActiveUnited KingdomIncorporated 2014Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

Accounts to 2025-01-31

IXBRL · 189 source facts · 14 selected values

Validation findings
XBRL valid
Reporting period
2024-02-01 to 2025-01-31
Extraction status
complete
Numeric facts
125
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2024-01-01.xsd
Currency
GBP
Source identifier
Prod224_2505_SC467513_20250131
Source archive
Accounts_Monthly_Data-May2025.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2024-01-31

IXBRL · 191 source facts · 14 selected values

Not assessed
legacy record
Reporting period
2023-02-01 to 2024-01-31
Extraction status
Legacy / not assessed
Numeric facts
123
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2022-01-01.xsd
Currency
GBP
Source identifier
Prod224_2366_SC467513_20240131
Source archive
Accounts_Monthly_Data-July2024.zip

Accounts to 2017-01-31

IXBRL · 102 source facts · 3 selected values

Not assessed
legacy record
Reporting period
2016-02-01 to 2017-01-31
Extraction status
Legacy / not assessed
Numeric facts
46
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2014-09-01.xsd
Currency
GBP
Source identifier
Prod224_0044_SC467513_20170131
Source archive
Accounts_Monthly_Data-July2017.zip

Accounts to 2016-01-31

IXBRL · 41 source facts · 10 selected values

Not assessed
legacy record
Reporting period
2015-02-01 to 2016-01-31
Extraction status
Legacy / not assessed
Numeric facts
15
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
uk-gaap-full-2009-09-01.xsd
Currency
GBP
Source identifier
Prod224_0034_SC467513_20160131
Source archive
Accounts_Monthly_Data-September2016.zip

Registered details

SC467513
Status
Active
Type
Private Limited Company
Incorporated
2014-01-15
Jurisdiction
—
Registered office
LIBERTY BUILDING, FORESTERHILL, ABERDEEN, AB25 2ZP

Classification

1 SIC codes
23101

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

0 SH01-derived rounds

No reconstructed allotment rounds.

Research and innovation

14 matched grants
Finding Needles in Haystacks: First-in-class soloMER drug candidates as precision medicine for autoimmune inflammation diseases.LeadActive
UKRI FLF · Fellowship · 2025-12-01 – 2028-12-01 · with 4 other participants
£527,682
whole project
Elasmogen LtdleadKU LeuvenUniversity of GlasgowUniversity Of ManchesterUniversity of Wisconsin–Madison
Enabling enhanced preclinical nuclear imaging at the University of Hull
MRC · Research Grant · 2022-10-31 – 2023-03-29 · with 5 other participants
£733,531
whole project
University of HullleadAptamer GroupElasmogen LtdGE Healthcare LimitedInvicroUrenco Power Technologies Ltd
CageTag: Caged Theranostics as a Universal Platform for Nuclear Medicine
EPSRC · Research Grant · 2022-03-31 – 2023-12-31 · with 3 other participants
£481,519
whole project
University of HullleadAptamer GroupElasmogen LtdGe Healthcare Limited
Targeting cytotoxic immunity for the resolution of neuropathic painActive
UKRI FLF · Fellowship · 2022-01-12 – 2026-10-10 · with 1 other participant
£1,142,255
whole project
University Of OxfordleadElasmogen Ltd
Targeting the pathogenic Th17 cell axis in autoimmunity:developing a portfolio of novel, rationally designed and innovatively delivered biologicsLead
UKRI FLF · Fellowship · 2021-12-01 – 2025-11-30 · with 9 other participants
£1,575,306
whole project
Elasmogen LtdleadGuy's and St Thomas' NHS Foundation TrustIntract Pharma LimitedIntract Pharma LtdQueen's University BelfastQueen'S University BelfastUniversity Of AberdeenUniversity of GlasgowUniversity Of OxfordUZ Leuven, Belgium
Bridging critical funding gap to deliver late-stage pre-clinical oncology assetsLead
Innovate UK · Feasibility Studies · 2020-06-01 – 2020-11-30
£232,489
awarded
Queen's university Belfast and Elasmogen Limited
Innovate UK · Knowledge Transfer Partnership · 2019-11-01 – 2022-01-31 · with 1 other participant
Queen's University Belfastlead£125,636
Elasmogen Limited—
University of Aberdeen and Elasmogen Limited
Innovate UK · Knowledge Transfer Partnership · 2018-12-01 – 2022-03-31 · with 1 other participant
University of Aberdeenlead£129,341
Elasmogen Limited—
Uncovering the pharmacology of a novel receptor target for age-related macular degeneration
BBSRC · Studentship · 2018-09-30 – 2022-12-31 · with 1 other participant
£0
whole project
University Of AberdeenleadElasmogen Ltd
SSA Uncovering the pharmacology of a novel receptor target
BBSRC · Studentship · 2018-09-30 – 2022-09-29 · with 1 other participant
£0
whole project
University Of AberdeenleadElasmogen Ltd
A Technology Platform for Next Generation VNAR Based Oncology Medicines
Innovate UK · Collaborative R&D · 2018-08-01 – 2021-03-31 · with 1 other participant
£438,407
awarded
Almac Discovery Limitedlead£662,847
Elasmogen Limited£438,407
Development of intracellular VNARs as novel tools to dissect intracellular biological processes
BBSRC · Research Grant · 2018-03-31 – 2021-03-30 · with 1 other participant
£346,536
whole project
Queen'S University BelfastleadElasmogen Ltd
soloMER™ Biologics: Next-generation therapeutics for the site-specific treatment of ocular diseasesLead
Innovate UK · Collaborative R&D · 2017-02-01 – 2019-01-31
£685,575
awarded
soloMER™ coated Nanoparticles or sNaPs™ - The development of optimised “escort” molecules for the targeted delivery of nanomedicine, anti-cancer therapeuticsLead
Innovate UK · Feasibility Studies · 2016-04-01 – 2017-02-28 · with 1 other participant
£68,964
awarded
Elasmogen Limitedlead£68,964
Queen's University Belfast£42,130